A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Advanced Solid Tumours Clinical Trial

Official title:

A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05514132
• Other study ID #: D5330C00017
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 23, 2022
• Est. completion date: April 1, 2025

Study information

• Verified date: May 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label study of ceralasertib given in combination with durvalumab in Chinese participants with advanced solid tumours. In each cohort, a monotherapy lead-in period (Cycle 0, duration of 7 or 14 days), prior to dosing with durvalumab, is added to investigate the PK profile and safety/tolerability of ceralasertib in Chinese participants.

This study is designed to investigate and characterise preliminary safety, tolerability, and PK of ceralasertib in DLT-evaluable Chinese participants

Description:

Primary Objective:

To assess the safety and tolerability of ceralasertib in combination with durvalumab in Chinese patients with advanced solid tumours refractory/resistant to prior SoC therapy or for which no appropriate SoC therapy exists.

Secondary Objective:

To characterise the PK profile of ceralasertib after single- and multiple-doses administration. To characterise the anti-tumour activity and efficacy of ceralasertib in combination with durvalumab in Chinese patients .

This is a Phase 1, open-label study of ceralasertib given in combination with durvalumab in Chinese patients with advanced solid tumours.Results from this study will provide dose rationale for future investigations.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 14
• Est. completion date: April 1, 2025
• Est. primary completion date: October 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent.

2. At least 18 years of age at the time of signing the ICF.

3. Histological or cytological confirmation advanced solid tumour with refractory/resistance to a prior line of anti-PD-1/PD-L1-containing therapy (received as monotherapy or in combination) or for which no SoC exists.

4. Ability to swallow oral medication intact and retain it.

5. ECOG/WHO performance status of 0 to 1.

6. Must have a life expectancy of at least 12 weeks.

7. Participant must have had a treatment-free interval of = 3 weeks from any prior therapy before the first dose of study treatment.

8. Body weight > 35 kg and no cancer-associated cachexia (eg, CTCAE Grade 2 or worse weight loss over the 3 months prior to the Screening Visit).

9. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

1. Inadequate bone marrow reserve or organ function

2. As judged by the investigator, any evidence of uncontrolled intercurrent illness, that in the investigator's opinion makes it undesirable for the participant to participate in the study.

3. Spinal cord compression, leptomeningeal disease, or brain metastases, unless asymptomatic, treated, stable, and not requiring continuous corticosteroids

4. As judged by the investigator, any active disease or condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy

5. History of another primary malignancy.

6. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, active bleeding diatheses, renal transplant, or active infection including any patient known to have hepatitis B, hepatitis C, and HIV.

7. Known history of HIV infection.

8. Active cardiacvascular disease be consider as clinical significant.

9. Active or prior documented autoimmune or inflammatory disorders

10. Prior exposure to a CHK1 or ATR inhibitor.

11. As judged by the investigator, any unresolved treatment-related toxicities from previous anti-cancer therapy of CTCAE v5.0 Grade = 2

12. Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.

13. Participants must not have experienced a toxicity that led to permanent discontinuation of prior anti-PD-1 or anti-PD-L1 immunotherapy.

14. Participants must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged

15. Participants with a known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients

16. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

17. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.

18. Previous enrolment in the present study.

19. For women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.

Related Conditions & MeSH terms

• Advanced Solid Tumours
• Neoplasms

Intervention

Drug:
• Ceralasertib
Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
• Durvalumab
Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.

Locations

Country	Name	City	State
China	Research Site	Beijing
China	Research Site	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of subjects with dose-limiting toxicity, as defined in the protocol.	Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optional therapeutic intervention, meets protocol-defined criteria.	From the first dose of study treatment Up to and including the end of cycle 1(each cycle is 28 days) .
Primary	Safety and tolerability in terms of adverse events	Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms (ECGs), safety and laboratory parameters	From the first dose of study treatment until 28 days after the last dose.
Secondary	Plasma ceralasertib concentration(Cmax)	Observed PK parameters of ceralasertib	Cycle 0 Day1 to Day7, Cycle1 Day1 and Cycle 1 Day 7 or Day 8. At the end of Cycle1(each cycle is 28 days)
Secondary	Area under the plasma concentration versus time curve(AUC)	Observed PK parameters of ceralasertib.	Cycle 0 Day1 to Day7, Cycle1 Day1 and Cycle1 Day7 or Day8. At the end of Cycle1(each cycle is 28 days)
Secondary	Overall response rate	Antitumor activity by evaluation of tumor response assessments using RECIST 1.1	At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28days) until objective disease progression as defined by RECIST version 1.1
Secondary	Duration of Response	Antitumor activity by evaluation of tumor response assessments using RECIST 1.1	At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28 days) until objective disease progression as defined by RECIST version 1.1
Secondary	Percentage Change in Tumour Size	Antitumor activity by evaluation of tumor response assessments using RECIST 1.1	At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28 days) until objective disease progression as defined by RECIST version 1.1
Secondary	Progression Free Survival	Antitumor activity by evaluation of tumor response assessments using RECIST 1.1	From start of treatment until the date of objective disease progression or death. (approximately 6 months).